P714 Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
Abstract Background The effect of Vedolizumab (VDZ), a gut-selective monoclonal anti-α4β7-integrin antibody approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC) has been demonstrated in clinical trials. The aim of this study was to describe a VDZ-treated patient population and...
Saved in:
Published in | Journal of Crohn's and colitis Vol. 12; no. supplement_1; pp. S472 - S473 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
UK
Oxford University Press
16.01.2018
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
The effect of Vedolizumab (VDZ), a gut-selective monoclonal anti-α4β7-integrin antibody approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC) has been demonstrated in clinical trials. The aim of this study was to describe a VDZ-treated patient population and assess long-term effectiveness and safety in clinical practice.
Methods
Observational and multicentre study in IBD patients treated with VDZ for at least a year. Effectiveness was evaluated with clinical scores and levels of faecal calprotectin (FC) and C-reactive protein (CRP) at 6 and 12 months. We also investigated the hospitalisations, surgeries, and adverse events.
Results
A total of 73 patients (43 UC and 30 CD) were analysed. Table 1 illustrates the baseline characteristics of the patients.
BASELINE CHARACTERISTICS
47% of the patients had a prior adverse event with azathioprine. VDZ was stopped in 17 patients (23%), 10 UC and 7 CD, due to lack or loss of response prior to the first year. Twenty-seven (63%) UC and 16 (53%) CD patients required dose escalation. At 6 months, 70% and 42% UC patients and 80% and 43% CD patients, respectively, achieved clinical response and remission. At 1 year, 58% and 35% UC and 47% and 43% CD patients maintained clinical response and remission, respectively. A reduction of CRP was accomplished in CD and UC. However, declining of FC was achieved during the follow-up in UC but not in CD (2256, 978, 729 vs. 1078, 703, 802 µg/g, basal, 6 and 12 months, respectively). The 8 CD patients who had been previously treated with ustekinumab avoided surgery at 1 year. Eight (19%) UC patients underwent colectomy and 4 (13%) CD patients needed surgery. Two patients had post-operative complications (paralytic ileus in UC and abdominal wall abscess in CD). Ten (23%) UC patients and 8 (27%) CD required hospitalisation. Six patients (8%) had adverse events during follow-up, mainly arthralgia, non-opportunistic infections and one infusion-related reaction. The concomitant use of corticosteroids or immunomodulators did not increase effectiveness. The absence of remission in UC and non-response in CD were associated with the number of prior treatments with anti-TNF.
Conclusions
One year of VDZ induces clinical response and remission in IBD patients who were refractory not only to anti-TNF but also to ustekinumab. VDZ is probably a good alternative in medically refractory and thiopurine intolerant IBD patients due to its reduced immunogenicity, with few adverse events, post-operative complications and hospitalisations. FC may not be a liable predictor of VDZ response in CD. |
---|---|
AbstractList | Abstract
Background
The effect of Vedolizumab (VDZ), a gut-selective monoclonal anti-α4β7-integrin antibody approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC) has been demonstrated in clinical trials. The aim of this study was to describe a VDZ-treated patient population and assess long-term effectiveness and safety in clinical practice.
Methods
Observational and multicentre study in IBD patients treated with VDZ for at least a year. Effectiveness was evaluated with clinical scores and levels of faecal calprotectin (FC) and C-reactive protein (CRP) at 6 and 12 months. We also investigated the hospitalisations, surgeries, and adverse events.
Results
A total of 73 patients (43 UC and 30 CD) were analysed. Table 1 illustrates the baseline characteristics of the patients.
BASELINE CHARACTERISTICS
47% of the patients had a prior adverse event with azathioprine. VDZ was stopped in 17 patients (23%), 10 UC and 7 CD, due to lack or loss of response prior to the first year. Twenty-seven (63%) UC and 16 (53%) CD patients required dose escalation. At 6 months, 70% and 42% UC patients and 80% and 43% CD patients, respectively, achieved clinical response and remission. At 1 year, 58% and 35% UC and 47% and 43% CD patients maintained clinical response and remission, respectively. A reduction of CRP was accomplished in CD and UC. However, declining of FC was achieved during the follow-up in UC but not in CD (2256, 978, 729 vs. 1078, 703, 802 µg/g, basal, 6 and 12 months, respectively). The 8 CD patients who had been previously treated with ustekinumab avoided surgery at 1 year. Eight (19%) UC patients underwent colectomy and 4 (13%) CD patients needed surgery. Two patients had post-operative complications (paralytic ileus in UC and abdominal wall abscess in CD). Ten (23%) UC patients and 8 (27%) CD required hospitalisation. Six patients (8%) had adverse events during follow-up, mainly arthralgia, non-opportunistic infections and one infusion-related reaction. The concomitant use of corticosteroids or immunomodulators did not increase effectiveness. The absence of remission in UC and non-response in CD were associated with the number of prior treatments with anti-TNF.
Conclusions
One year of VDZ induces clinical response and remission in IBD patients who were refractory not only to anti-TNF but also to ustekinumab. VDZ is probably a good alternative in medically refractory and thiopurine intolerant IBD patients due to its reduced immunogenicity, with few adverse events, post-operative complications and hospitalisations. FC may not be a liable predictor of VDZ response in CD. |
Author | Nos, P Maroto, N Boscá-Watts, M Navarro-Cortes, P Ferrer, I Iborra, M Beltran, B Garcia-Morales, N Hinojosa, J Sáez-González, E Minguez, M |
Author_xml | – sequence: 1 givenname: M surname: Iborra fullname: Iborra, M organization: La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain – sequence: 2 givenname: N surname: Maroto fullname: Maroto, N organization: Hospital de Manises, Department of Gastroenterology, Manises, Spain – sequence: 3 givenname: P surname: Navarro-Cortes fullname: Navarro-Cortes, P organization: University Clinic Hospital of Valencia, Department of Gastroenterology and Hepatology, Valencia, Spain – sequence: 4 givenname: B surname: Beltran fullname: Beltran, B organization: La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain – sequence: 5 givenname: M surname: Boscá-Watts fullname: Boscá-Watts, M organization: University Clinic Hospital of Valencia, Department of Gastroenterology and Hepatology, Valencia, Spain – sequence: 6 givenname: I surname: Ferrer fullname: Ferrer, I organization: Hospital de Manises, Department of Gastroenterology, Manises, Spain – sequence: 7 givenname: N surname: Garcia-Morales fullname: Garcia-Morales, N organization: La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain – sequence: 8 givenname: E surname: Sáez-González fullname: Sáez-González, E organization: La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain – sequence: 9 givenname: J surname: Hinojosa fullname: Hinojosa, J organization: Hospital de Manises, Department of Gastroenterology, Manises, Spain – sequence: 10 givenname: M surname: Minguez fullname: Minguez, M organization: University Clinic Hospital of Valencia, Department of Gastroenterology and Hepatology, Valencia, Spain – sequence: 11 givenname: P surname: Nos fullname: Nos, P organization: La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain |
BookMark | eNptkMtOwzAQRS1UJNrCF7DxB-DWrp2Hl6jiJVWCBbCNxo8IR4kdHFfQfj1pywqxmlncczVzZmjig7cIXTO6YFTypdU6kEbrZdN8s5IuSsHO0JSVRU6EKOTkuHMipcgv0GwYGkozmRXlFO1fCibwuzWhdfttB-oGg8dg7OcWksWhTy547DzurHEa2naHo60j6BTibowanD5c6LfReUucT6G1EXwaibqFroNjTIUv22LjBguDxT0kZ30aLtF5De1gr37nHL3d372uH8nm-eFpfbshmhUlI5kuaU65zE2uJAdFpYSSroDWzEooNLVMKbHiRcalzHKhMrrK1ficNkaLLOdzxE-9OoZhGK-v-ug6iLuK0eqgrzroq0Z91UlfNeobqcWJCtv-X4D8AX4AfB955g |
CitedBy_id | crossref_primary_10_1111_1751_2980_12748 crossref_primary_10_1007_s12325_023_02457_6 |
ContentType | Journal Article |
Copyright | Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 |
Copyright_xml | – notice: Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 |
DBID | AAYXX CITATION |
DOI | 10.1093/ecco-jcc/jjx180.841 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Abstracts of the 13th Congress of ECCO Vienna, Austria, February 14-17, 2018 |
EISSN | 1876-4479 |
EndPage | S473 |
ExternalDocumentID | 10_1093_ecco_jcc_jjx180_841 10.1093/ecco-jcc/jjx180.841 |
GroupedDBID | --- --K 0R~ 1B1 1~. 1~5 4.4 48X 4G. 5GY 5WD 7-5 71M AABZA AACZT AAJQQ AAMVS AAOGV AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP ABBQC ABDBF ABEUO ABIXL ABJNI ABNHQ ABPTD ABQLI ABQNK ABWST ABXVV ACGFS ACUFI ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADJQC ADQBN ADRIX ADRTK ADVEK ADYVW AEGPL AEJOX AEKER AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AGYEJ AJEEA AJRQY ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT ATGXG AVWKF AXUDD BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM CDBKE CS3 DAKXR DILTD DU5 EBS EJD ENERS EO8 EO9 EP2 EP3 F5P FDB FECEO FLUFQ FNPLU FOEOM FOTVD FQBLK GAUVT GBLVA GJXCC H13 HAR IHE J1W J21 KBUDW KOP KSI KSN MHKGH MO0 N9A NOMLY NOYVH O-L OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OPAEJ OVD OWPYF OZT P-8 P-9 P2P PAFKI PC. PEELM Q5Y RIG ROX RPZ RUSNO RXO SDF SDG SEL TEORI TJX YAYTL YKOAZ YXANX AAYXX CITATION |
ID | FETCH-LOGICAL-c1781-5c8060396d6b93ab099a802a0f1e9a7c0e1bb42375399564b5026b578cddc4563 |
ISSN | 1873-9946 |
IngestDate | Fri Aug 23 03:27:18 EDT 2024 Wed Aug 28 03:21:15 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1781-5c8060396d6b93ab099a802a0f1e9a7c0e1bb42375399564b5026b578cddc4563 |
OpenAccessLink | https://academic.oup.com/ecco-jcc/article-pdf/12/supplement_1/S472/23745190/jjx180.841.pdf |
ParticipantIDs | crossref_primary_10_1093_ecco_jcc_jjx180_841 oup_primary_10_1093_ecco-jcc_jjx180_841 |
PublicationCentury | 2000 |
PublicationDate | 20180116 2018-01-16 |
PublicationDateYYYYMMDD | 2018-01-16 |
PublicationDate_xml | – month: 01 year: 2018 text: 20180116 day: 16 |
PublicationDecade | 2010 |
PublicationPlace | UK |
PublicationPlace_xml | – name: UK |
PublicationTitle | Journal of Crohn's and colitis |
PublicationYear | 2018 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
SSID | ssj0059578 |
Score | 2.1710308 |
Snippet | Abstract
Background
The effect of Vedolizumab (VDZ), a gut-selective monoclonal anti-α4β7-integrin antibody approved for treatment of Crohn’s disease (CD) and... |
SourceID | crossref oup |
SourceType | Aggregation Database Publisher |
StartPage | S472 |
Title | P714 Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELeqTUK8ID7F-JIfkHjovNmJkziPa2EaSJ2Q2NDeIttxRKc2KW0KrP8c_xrnOF9FBTFeotayTonvp9zl7n53CL3WltHoGUGE4DHhgmZEcS2JBveemSDkumLxT87Ds0v-4Sq4Ggx-9qqW1qU60pudvJL_0SqsgV4tS_YWmm2FwgL8Bv3CFTQM13_S8ceI8eFnkxaz6WY9l8qVYg5lar6upc3_L5pSxrnLx8xuhmARl9WMnZu6eHJaLGzE3ZBpXhYzA7bLTg3IAClzl4FXxXfTZnKaRqyrP3i142XxxU1pcYQ5W13Xuu3vAXDVXKMuBjuRy6Ka5NTlhM7lN9sZkoxtHfBqi4M2MrNy6UK2o368gtlSOeLolPUrVkQ-ieM68GiatZBw7sbKtO9lr4e_lZ1xWgVME9Z7337ibvBPbbvhr7_TLrieWQDXglxrbU3E9Q8m6JFwXbe2-3D_Zh_bqkWXr_cTKyYBMYkTkgjbOGHfi-IAvv73T0ZvR6eNMxDAWsXGbB66aXwV-8fN3Rx397LlHFnCZc_XubiP7tXqxCcOcQ_QwOQP0Z1JXYbxCG0s8HAPeIdY5riBHXaww9Mct7DDHexga4p3wg73YYcr2OEadriB3WN0efruYnxG6iEeRLNIMBJoQUPqx2EaqtiXCr5IpKCepBkzsYw0NUwpW5sVVCRrrgLqhQpOTaepBu_ef4L28iI3TxE2UZyGHs38KOOcZyCTZTzN0kzQ1OOKH6DD5vSShevVkvxFZwfoDZzwzp1ke-ez2wl-ju52wH-B9srl2rwE17VUr2p4_AKWY6AF |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P714+Vedolizumab%2C+an+adequate+option+in+medically+refractory+and+thiopurine-intolerant+inflammatory+bowel+disease+patients&rft.jtitle=Journal+of+Crohn%27s+and+colitis&rft.au=Iborra%2C+M&rft.au=Maroto%2C+N&rft.au=Navarro-Cortes%2C+P&rft.au=Beltran%2C+B&rft.date=2018-01-16&rft.issn=1873-9946&rft.eissn=1876-4479&rft.volume=12&rft.issue=supplement_1&rft.spage=S472&rft.epage=S473&rft_id=info:doi/10.1093%2Fecco-jcc%2Fjjx180.841&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ecco_jcc_jjx180_841 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-9946&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-9946&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-9946&client=summon |